Hemophagocytic Lymphohistiocytosis
Hemophagocytic Lymphohistiocytosis Market

Hemophagocytic Lymphohistiocytosis (HLH) is a life-threatening disorder characterized by unbridled activation of cytotoxic T lymphocytes, natural killer (NK) cells, and macrophages resulting in hypercytokinemia and immune-mediated injury of multiple organ systems.


Hemophagocytic lymphohistiocytosis (HLH) is a disease with various underlying causes. There are many names used to describe this condition. Familial hemophagocytic lymphohistiocytosis (FHL) refers to genetic forms caused by an abnormal variant in a gene. 


Macrophage activation syndrome (MAS) is the term used for hemophagocytic lymphohistiocytosis in people with an autoimmune or autoinflammatory disease. This is a type of secondary Hemophagocytic Lymphohistiocytosis.  


The onset and severity of hemophagocytic lymphohistiocytosis can vary significantly from one person to another. Generally, affected individuals develop fevers, a rash, an abnormally large liver (hepatomegaly), and an abnormally large spleen (splenomegaly). However, these initial signs and symptoms are described as nonspecific. Affected individuals may also have anemia, thrombocytopenia, neurological symptoms including seizures, mental status changes and irritability, paralysis (palsy) of absolute cranial nerves, and problems coordinating voluntary movements (ataxia).


Hemophagocytic Lymphohistiocytosis Epidemiological Segmentation 

The Epidemiological Segmentation of Hemophagocytic Lymphohistiocytosis in 7MM from 2017 to 2030 is segmented as:- 

  • Total Incident Cases of Hemophagocytic Lymphohistiocytosis
  • Gender-specific Incident Cases of Hemophagocytic Lymphohistiocytosis
  • Age-specific Incident Cases of Hemophagocytic Lymphohistiocytosis
  • Subtype-specific Incident Cases of Hemophagocytic Lymphohistiocytosis


Hemophagocytic Lymphohistiocytosis Epidemiology 

  • The total incident population of Hemophagocytic Lymphohistiocytosis in 7MM in 2017 was 4,435
  • The incidence population of Hemophagocytic Lymphohistiocytosis in 2017 in the United States was 415
  • Men are slightly more affected than females


Hemophagocytic Lymphohistiocytosis Market

The market size of Hemophagocytic Lymphohistiocytosis in 2017 was USD 6.1 million. 


Hemophagocytic Lymphohistiocytosis Emerging Drugs

The emerging drugs of the Hemophagocytic Lymphohistiocytosis market are 

  • Tadekinig alfa (IL-18BP)

And many others.  

 

Hemophagocytic Lymphohistiocytosis Key Players

The key players in the Hemophagocytic Lymphohistiocytosis market are

  • AB2 Bio

And many others.